Perioperative use of Epsilon-aminocaproic acid in patients with the diagnosis of prostatic benign hyperplasia

Abstract

Introduction: To reduce intraoperative blood loss and the use of transfusion requirements, antifibrinolytic agents that repermeabilize a bleeding vessel are used. Objective: To determine the behavior of blood loss in patients proposed for surgical treatment due to benign prostatic hyperplasia. Method: A quasiexperimental study was carried out with a single group in the anesthesiology and resuscitation service of Manuel Ascunce Domenech University Hospital in the period from May 1, 2005 to May 1, 2013. For information processing, arithmetic mean was used in the quantitative variables. The qualitative variables are described through absolute and relative frequencies. To calculate the differences between groups, in the case of qualitative variables we used the Chi square test. The significance level used was 0.05. For those variables that differ in the groups to be compared, a multivariate analysis was performed in order to determine whether they have an influence on bleeding or not. The information was processed using SPSS 15.0. Results: The use of anesthetics and therapeutic methods was associated with Epsilon-aminocaproic acid; the risk of blood loss over 750 ml when the anesthetic time and drug are not used was associated with blood loss. Conclusion: It was shown that the use of Epsilon-aminocaproic acid is a restrictive transfusional measure and an option in patients performed intravesical prostatectomy.

Keywords

• transfusión sanguínea
• ácido épsilon aminocaproico
• hiperplasia benigna de próstata